Head-to-head · WeighScore
NextMeds vs PlushCare
The verdict
PlushCare takes it — 74.5/100 to 66.3/100.
PlushCare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Established virtual primary-care telehealth platform (subsidiary of Transcarent, Inc., a Delaware corporation, alongside Accolade, 2nd.MD, and 98point6 by Transcarent).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NextMeds | PlushCare |
|---|---|---|
| WeighScore | 66.3/100 | 74.5/100 |
| Grade | C | C |
| Scorecard rank | #191 | #63 |
| Semaglutide | $129/mo (plus a separate fee, compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | $179/mo (plus a separate fee, compounded) | $399/mo (starting dose, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #191 · C
Strengths
- Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
- Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
- Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
- Free, no-obligation online assessment before you pay anything
Where it loses points
- Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
- Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
- A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #63 · C
Strengths
- Available in all 50 states
- Appointments with US board-certified physicians, not nurse practitioners only
- Virtual primary care — the same doctor can manage GLP-1s alongside other health needs
- Owned by Transcarent, a venture-backed health platform with a named corporate parent
Where it loses points
- Facing a California class action alleging deceptive subscription enrollment and unauthorized charges after cancellation
- GLP-1 prescribing is up to the clinician at the visit — not guaranteed at signup
- BBB complaints center on the membership cancellation process
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.